Short communication

Noninvasive ECG imaging (ECGI): Mapping the arrhythmic substrate of the human heart

Yoram Rudy
Washington University, St. Louis, USA

ARTICLE INFO

Article history:
Received 7 February 2017
Accepted 21 February 2017
Available online 27 February 2017

ABSTRACT

This short communication accompanies my presentation at the International Congress on Sudden Cardiac Death held in Prague, March 30–April 1, 2017. It summarizes briefly studies of the cardiac electrophysiological substrate in patients with hereditary arrhythmogenic syndromes – the Long QT and Brugada syndromes – conducted noninvasively, in situ, using Electrocardiographic Imaging (ECGI). The same noninvasive approach was used to map the electrophysiological substrate of a post-infarction myocardial scar and to relate this substrate to the pattern of activation during reentrant ventricular tachycardia. My thoughts about a potential role for ECGI in cardiac research and clinical care are also expressed briefly, with examples from on-going work in my laboratory.

© 2017 Elsevier B.V. All rights reserved.

Electrocardiographic Imaging (ECGI) is a novel imaging modality, developed in my laboratory [1,2], that maps noninvasively cardiac electrical activity on the heart epicardial surface. In ECGI, a multi-electrode vest (or strips) records 250 body-surface electrocardiograms; then, using these electrocardiograms together with geometrical information from a CT or MRI scan, a mathematical algorithm reconstructs electrical potentials, electrograms, activation sequences (isochrones) and repolarization patterns on the heart surface (Fig. 1). ECGI has been applied to study the arrhythmic substrate in hereditary arrhythmogenic syndromes – Long QT syndrome (LQTS) and Brugada syndrome (BrS). In addition, ECGI was used to map the electrical substrate of post myocardial infarction (MI) scars in relation to the activation pattern of ventricular tachycardia (VT).

In LQTS [3], maps of epicardial activation, recovery time (RT) and activation-recovery intervals (ARI; surrogate for local action potential duration (APD)) were reconstructed and compared with those of healthy volunteers. Activation was normal in all patients. However, RT and ARI were prolonged relative to control, indicating delayed repolarization and abnormally long APD. ARI prolongation was spatially heterogeneous, with repolarization gradients much steeper than control. This defines a substrate for reentrant arrhythmias, not detectable by surface ECG. Steeper dispersion of repolarization in symptomatic patients suggests a possible role for ECGI in risk stratification.

ECGI in BrS patients [4] revealed the coexistence of structurally-based abnormal conduction and abnormal repolarization in the electrophysiological (EP) substrate. Different from LQTS, the BrS abnormal substrate was confined to the right ventricular outflow tract (RVOT). ECGI could differentiate between BrS patients (malignant and highly arrhythmogenic) and non-BrS right bundle branch block (RBBB) patients (generally considered benign) who have similar body surface ECGs, based on major differences in the cardiac EP substrate.

In ischemic cardiomyopathy patients, abnormal EP scar substrate was determined based on low electrogram voltage, and scar heterogeneity was characterized by presence of electrogram fractionation. Late potentials were also reconstructed. These parameters, reconstructed in sinus rhythm, differentiated between patients with VT and without VT. ECGI mapping during VT demonstrated close relationship between the reentry circuit and scar EP substrate [5–8].

I was asked by Professor Peter Schwartz to provide an “eye to the future” in regards to ECGI applications. While one cannot predict the future with any degree of certainty, I believe that ECGI can play a central role in cardiology on two accounts: basic research – providing much needed understanding of the mechanisms of electrophysiological disorders and arrhythmias in the human heart in situ, and clinical care – as a noninvasive tool for patient-specific and mechanism-based diagnosis, risk stratification for arrhythmia and sudden death, planning and guidance of therapy, follow up for evaluation of therapy over time, and providing the basis for noninvasive ablation procedures in the future.

At present, ECGI-related research in my laboratory and in collaboration with other labs is progressing towards these goals. Together with researchers from Barts Heart Center in London, UK (Pier Lambiase, principal investigator) we completed a study of the substrate in hereditary arrhythmogenic right ventricular cardiomyopathy (ARVC). Building on our previous ECGI studies of atrial fibrillation (AF) [9,10], we are conducting a longitudinal study of the mechanism(s) underlying persistent AF and its recurrence post-ablation. Through noninvasive multi-modality approach (ECGI, tagged MRI and speckles echo) we extend a previous study [11] by imaging the electrical and mechanical properties of failing hearts in...
heart failure patients undergoing cardiac resynchronization therapy. We follow changes in these properties over time in an attempt to characterize reverse-remodeling processes in these hearts. Together with collaborators from cardiology (Phillip Cuculich) and radiation oncology (Clifford Robinson) at Washington University, we have started to test a noninvasive stereotactic ablation radiotherapy for VT with very promising results as evaluated for longer than one-year post-procedure [12]. In short, these are exciting times with new electrophysiological data obtained from the in situ human heart using a novel imaging modality for noninvasive mapping. My hope is that better understanding of the electrophysiologic cardiac substrate and the mechanisms of human cardiac arrhythmias will lead to improved prevention and treatment of electrophysiological disturbances of the heart.

Funding sources

The studies summarized in this communication were supported by NIH – National Heart, Lung and Blood Institute grants R01-HL-033343 and R01-HL-049054 to Yoram Rudy.

Conflict of interest

Yoram Rudy receives royalties from CardiolInsight Technologies (CIT). CIT does not support any research conducted in Dr. Rudy’s laboratory.

References


